Astegolimab is a monoclonal antibody that blocks the IL-33 receptor, ST2, a protein involved in inflammation. It is being studied as a potential treatment for conditions like severe asthma and chronic obstructive pulmonary disease (COPD). Astegolimab is designed to target a pathway involved in inflammation, potentially reducing exacerbations in these conditions. The directory classifies it as a clinical API with a biotechnology source/manufacturing origin. Other names for this substance include AMG-282, Astegolimab [WHO-DD] and MSTT-1041A. Its PubChem SID is 402425721.
Astegolimab
| CAS No | 2173054-79-8 |
|---|---|
| Molecular Formula | C₆₄₂₄H₉₈₇₈N₁₆₉₄O₂₀₃₀S₅₂ |
| Molecular Weight | ~ 144.98 kDa |
| Synonyms | NA |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Astegolimab is a monoclonal antibody that blocks the IL-33 receptor, ST2, a protein involved in inflammation. It is being studied as a potential treatment for conditions like severe asthma and chronic obstructive pulmonary disease (COPD).
The listed CAS number is 2173054-79-8.
The listed molecular formula is C₆₄₂₄H₉₈₇₈N₁₆₉₄O₂₀₃₀S₅₂.
The listed molecular weight is ~ 144.98 kDa.
NA.
The source lists AMG-282, Astegolimab [WHO-DD] and MSTT-1041A.